(levonorgestrel and ethinyl estradiol tablets USP)
Each Trivora cycle of 28 tablets consists of three different drug phases as follows: Phase 1 comprised of 6 blue tablets, each containing 0.050 mg of levonorgestrel (d (-)-13 beta-ethyl-17-alpha-ethinyl-17-beta-hydroxygon-4-en-3-one), a totally synthetic progestogen, and 0.030 mg of ethinyl estradiol (19-nor-17α-pregna-1,3,5(10)-trien-20-yne-3, 17-diol); phase 2 comprised of 5 white tablets, each containing 0.075 mg levonorgestrel and 0.040 mg ethinyl estradiol; and phase 3 comprised of 10 pink tablets, each containing 0.125 mg levonorgestrel and 0.030 mg ethinyl estradiol; then followed by 7 peach inert tablets.
Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
Media Articles Related to Trivora (Levonorgestrel / Estradiol / Levonorgestrel / Estradiol / Levonorgestrel / Estradiol)
Research reveals more than half of young women who have abortions were using contraception when they fell pregnant
Source: Abortion News From Medical News Today [2014.04.30]
Reproductive health charity Marie Stopes UK has launched the findings of the first research in the UK into the contraceptive use of women aged 16-24 having one or more abortions.
New research shows a statistical significant association between increased LARC usage and reduction in teenage pregnancy and abortion rates in England
Source: Abortion News From Medical News Today [2014.11.27]
New findings, published in the International Journal of Women's Health, show increased long-acting reversible contraception (LARC) usage in England was significantly associated with decreased...
Free birth control reduces teen pregnancies and abortions
Source: Abortion News From Medical News Today [2014.10.03]
Teens who received free contraception and were educated about the pros and cons of various birth control methods were dramatically less likely to get pregnant, give birth or get an abortion compared...
Clinical Trials Related to Trivora (Levonorgestrel / Estradiol / Levonorgestrel / Estradiol / Levonorgestrel / Estradiol)
Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects [Recruiting]
A crossover study to assess the effect of repeated doses of fostamatinib on the levels of
oral contraceptive (Microgynon® 30) in the blood of healthy female subjects. The study will
consist of a screening period of up to 35 days, followed by 2 treatment periods (28 days
each) of an oral contraceptive (Microgynon® 30) in the absence and presence of fostamatinib.
The study will also evaluate the safety and tolerability of fostamatinib in combination
with an oral contraceptive
AZD6140 Oral Contraceptive Interaction Study [Recruiting]
A Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female Subjects [Recruiting]
A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil. [Completed]
The purpose of the study was to compare the contraceptive efficacy and safety of the
transdermal patch to Triphasil.
A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens [Completed]
This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy,
reproductive-aged women using three different regimens of oral contraceptives (OCs). Two
extended regimen OCs, Seasonale (levonorgestrel/ethinyl estradiol 0. 15/0. 03 mg for 84 days
followed by 7 days of placebo), and Seasonique (levonorgestrel/ethinyl estradiol 0. 15/0. 03 mg
for 84 days followed by 7 days of ethinyl estradiol 0. 01 mg), and a 28-day regimen OC, Portia
(levonorgestrel/ethinyl estradiol 0. 15/0. 03 mg for 21 days followed by 7 days of placebo).
Page last updated: 2014-11-27